CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2018—For diabetes type 2 patients with cardiovascular disease, findings of a new study support clinicians’ use of serial measures of NT-proBNP concentrations to make critical treatment decisions easier by basing them on risk of major cardiovascular events, including heart failure.
Read More »Serial NT-proBNP found to identify risk for adverse CV outcomes
